Evaxion announces completion of ads ratio change

Copenhagen, denmark, january 14, 2025 - evaxion biotech a/s (nasdaq: evax) (“evaxion” or the “company”), a clinical-stage techbio company specializing in developing ai-immunology™ powered vaccines, today announced that the company's previously disclosed ratio change of its american depositary shares (“adss”) to its ordinary shares, dkk 1 nominal value (the “ads ratio”), has been made effective.

EVAX Ratings Summary

EVAX Quant Ranking